Molecular docking confirmed that TFP is a GPX4 inhibitor, and elevated GPX4 expression in oral cancer biopsies was associated with poor prognosis [82], suggesting that targeting ferroptosis can effectively suppress OSCC progression and represent a novel strategy for cancer therapy (Table 6). This evidence concerns the gene GPX4 and cancer.